Jean-Marie Cuillerot, M.D., has been appointed chief medical officer of Agenus Inc. Dr. Cuillerot initially joined Agenus in 2016 as VP and Global Head of Clinical Development.
Jeffrey Young has become chief financial officer, treasurer, and secretary of Juniper Therapeutics Inc.
Two VPs have been named at TGaS Advisors. Tom Goga has been named to lead Field Operations, which also includes Incentive Compensation, and Rich Waite will head Commercial Learning & Development.
Responding to demands from cities across the country, NYU School of Medicine’s Department of Population Health, NYU’s Robert F. Wagner School of Public Service and the National Resource Network – with support from the Robert Wood Johnson Foundation – have launched the City Health Dashboard.
On February 9, Pharmapalooza – the annual healthcare agency battle of the bands event to benefit The Children’s Hospital at Montefiore (CHAM) – hit the stage at B.B. King Blues Club and Grill in Times Square.
The New Jersey Rare Disease Alliance will hold its annual Rare Disease Day commemoration on February 27 at the New Jersey Business and Industry Association (NJBIA).
Ceres Nanosciences Inc., a Prince William Science Accelerator startup company, announced the completion of a $3 million Series A financing as part of a larger $9 million Series A round. GreyBird Ventures, an early-stage venture fund firm, is leading the round with a commitment of up to $5.5 million over the next year and additional support. The funding will support the acceleration to market of a highly-sensitive diagnostic test for Lyme disease.
Revenues in 2016 were $21.9 billion, an increase of 11% compared to 2015, primarily due to the inclusion – following the closing on August 2, 2016 – of the results of the Actavis Generics business.
Purdue Pharma LP, Virginia Governor Terry McAuliffe, and the Virginia Secretary of Health and Human Resources have announced the formation of a private-public partnership to enhance utilization of the state prescription monitoring program as part of the solution to address the opioid crisis.
Overall, the prospects for the sector remain strong, linked to the expected growth in healthcare. There is a strong case for investment in particular segments, subject to appropriate valuation and due diligence. This report highlights some of the trends that should be in the minds of CEOs, CFOs and investors.
